Sign up to access all valuation multiples
NanoRepro AG is engaged in the development, manufacturing, and distribution of CE-certified rapid diagnostic tests (self-tests) and food supplements for both, home and professional use.
16
LTM Revenue $13.2M
LTM EBITDA -$3.1M
$17.6M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
NanoRepro has a last 12-month revenue (LTM) of $13.2M and a last 12-month EBITDA of -$3.1M.
In the most recent fiscal year, NanoRepro achieved revenue of $5.4M and an EBITDA of -$4.0M.
NanoRepro expects next 12-month revenue of XXX and NTM EBITDA of XXX
See NanoRepro valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $13.2M | XXX | $5.4M | XXX | XXX | XXX |
| Gross Profit | n/a | XXX | $3.4M | XXX | XXX | XXX |
| Gross Margin | n/a | XXX | 63% | XXX | XXX | XXX |
| EBITDA | -$3.1M | XXX | -$4.0M | XXX | XXX | XXX |
| EBITDA Margin | -23% | XXX | -74% | XXX | XXX | XXX |
| EBIT | -$3.5M | XXX | -$4.0M | XXX | XXX | XXX |
| EBIT Margin | -27% | XXX | -74% | XXX | XXX | XXX |
| Net Profit | -$2.3M | XXX | -$2.4M | XXX | XXX | XXX |
| Net Margin | -18% | XXX | -44% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of September 3, 2025, NanoRepro's stock price is EUR 2 (or $2).
NanoRepro has current market cap of EUR 24.2M (or $28.1M), and EV of EUR 15.1M (or $17.6M).
See NanoRepro trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $17.6M | $28.1M | XXX | XXX | XXX | XXX | $-0.19 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of September 3, 2025, NanoRepro has market cap of $28.1M and EV of $17.6M.
NanoRepro's trades at 3.3x EV/Revenue multiple, and -4.4x EV/EBITDA.
Equity research analysts estimate NanoRepro's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
NanoRepro has a P/E ratio of -12.1x.
See valuation multiples for NanoRepro and 15K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $28.1M | XXX | $28.1M | XXX | XXX | XXX |
| EV (current) | $17.6M | XXX | $17.6M | XXX | XXX | XXX |
| EV/Revenue | 1.3x | XXX | 3.3x | XXX | XXX | XXX |
| EV/EBITDA | -5.7x | XXX | -4.4x | XXX | XXX | XXX |
| EV/EBIT | -5.0x | XXX | -4.4x | XXX | XXX | XXX |
| EV/Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| P/E | -12.1x | XXX | -11.8x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | 1.6x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialNanoRepro's last 12 month revenue growth is 52%
NanoRepro's revenue per employee in the last FY averaged $0.3M, while opex per employee averaged $0.5M for the same period.
NanoRepro's rule of 40 is -92% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
NanoRepro's rule of X is 106% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for NanoRepro and other 15K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 52% | XXX | 99% | XXX | XXX | XXX |
| EBITDA Margin | -23% | XXX | -74% | XXX | XXX | XXX |
| EBITDA Growth | -82% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | -92% | XXX | -22% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 106% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.3M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.5M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 138% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Australian Clinical Labs | XXX | XXX | XXX | XXX | XXX | XXX |
| Clarity Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| CurveBeam AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Cyclopharm | XXX | XXX | XXX | XXX | XXX | XXX |
| Healius | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
NanoRepro acquired XXX companies to date.
Last acquisition by NanoRepro was XXXXXXXX, XXXXX XXXXX XXXXXX . NanoRepro acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 65K+ M&A deals.
Start Free Trial| Where is NanoRepro headquartered? | NanoRepro is headquartered in Germany. |
| How many employees does NanoRepro have? | As of today, NanoRepro has 16 employees. |
| Is NanoRepro publicy listed? | Yes, NanoRepro is a public company listed on ETR. |
| What is the stock symbol of NanoRepro? | NanoRepro trades under NN6 ticker. |
| When did NanoRepro go public? | NanoRepro went public in 2008. |
| Who are competitors of NanoRepro? | Similar companies to NanoRepro include e.g. Australian Clinical Labs, Clarity Pharmaceuticals, CurveBeam AI, Cyclopharm. |
| What is the current market cap of NanoRepro? | NanoRepro's current market cap is $28.1M |
| What is the current revenue of NanoRepro? | NanoRepro's last 12 months revenue is $13.2M. |
| What is the current revenue growth of NanoRepro? | NanoRepro revenue growth (NTM/LTM) is 52%. |
| What is the current EV/Revenue multiple of NanoRepro? | Current revenue multiple of NanoRepro is 1.3x. |
| Is NanoRepro profitable? | Yes, NanoRepro is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of NanoRepro? | NanoRepro's last 12 months EBITDA is -$3.1M. |
| What is NanoRepro's EBITDA margin? | NanoRepro's last 12 months EBITDA margin is -23%. |
| What is the current EV/EBITDA multiple of NanoRepro? | Current EBITDA multiple of NanoRepro is -5.7x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
